Does Olanzapine Warrant Clinical Pharmacokinetic Monitoring in Schizophrenia?

Author： Schwenger Erin   Dumontet Jane   Ensom Mary H.H.  

Publisher： Adis International

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.50, Iss.7, 2011-07, pp. : 415-428

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bifeprunox: beneficial in schizophrenia?

By  

Inpharma, Vol. 1, Iss. 1570, 2007-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Predictor of treatment response in schizophrenia?

By  

Inpharma, Vol. 1, Iss. 1280, 2001-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Does Oxcarbazepine Warrant Therapeutic Drug Monitoring?: A Critical Review

By Bring Penny   Ensom Mary H.H.  

Clinical Pharmacokinetics, Vol. 47, Iss. 12, 2008-01 ,pp. : 767-778

Adis International

Access to resources Recommend Favorite

Can Pharmacokinetic Monitoring Improve Clinical Use of Fluorouracil?

By Young A.M.   Daryanani S.   Kerr D.J.  

Clinical Pharmacokinetics, Vol. 36, Iss. 6, 1999-06 ,pp. : 391-398

Adis International

Access to resources Recommend Favorite

Atypical antipsychotics cause diabetes mellitus in schizophrenia?

By  

Inpharma, Vol. 1, Iss. 1289, 2001-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite